ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
“The realization that this transformation of MHC- to MHC+ could rescue exhausted or immune-evaded T cells was the basis of our Cancer Moonshot announced in 2016 .
- “The realization that this transformation of MHC- to MHC+ could rescue exhausted or immune-evaded T cells was the basis of our Cancer Moonshot announced in 2016 .
- I very much look forward to elaborating on the details with Dr. Sam Chang at the AUA conference,” said Dr. Patrick Soon-Shiong.
- Hosting Dr. Soon-Shiong will be Dr. Sam S. Chang, M.D., Professor of Urology and Chief Surgical Officer of the Vanderbilt Ingram Cancer Center.
- Dr. Chang was a principal investigator for ImmunityBio’s QUILT 3.032 study, which produced the data on which the FDA approval was based.